Embryonal rhabdomyosarcoma (ERMS) is the most common type of soft tissue cancer in children, accounting for 70% to 75% of all childhood rhabdomyosarcomas. It develops from immature cells that would normally grow into skeletal muscle, and it most often appears in children under 5 years old. Despite the name, it has nothing to do with embryos or pregnancy. The “embryonal” label refers to the fact that the cancer cells resemble the earliest stages of muscle development.
Where It Develops
ERMS can form almost anywhere in the body where skeletal muscle exists, but certain locations are far more common than others. The head and neck region is the most frequent site, particularly the area around the eye socket (the orbit) and spaces near the base of the skull called parameningeal sites. The genitourinary tract is the second most common location, including the bladder, prostate, and the area around the testicles in boys or the vagina in girls.
Less common head and neck sites include the nasal cavity, nasopharynx, ear, sinuses, and soft tissue of the face. Occasionally ERMS appears in the oral cavity, involving the tongue, lip, or palate, though this is rare.
Symptoms Depend on Location
Because ERMS grows in different parts of the body, symptoms vary widely. A tumor near the eye can push the eyeball forward (a condition called proptosis), cause double vision, or lead to swelling that looks like a persistent infection. Tumors in the sinuses or nasal area may mimic chronic sinusitis. Genitourinary tumors can cause urinary retention, a visible scrotal mass, or blood in the urine. In rare cases where the tumor develops near the bile ducts, jaundice can be the first sign.
Some tumors grow slowly and produce no pain at all, discovered only when a parent notices a lump or a doctor feels something unusual during a routine exam. Others grow rapidly and cause symptoms within weeks.
Who Gets It
ERMS peaks in children between birth and age 4, with roughly 4 cases per 1 million children in that age group. Boys are affected about 1.5 times more often than girls. The embryonal subtype makes up 57% of all rhabdomyosarcoma cases in the national SEER cancer database, making it by far the dominant form of this disease.
While it primarily affects young children, ERMS also occurs in adolescents and young adults, though less frequently. There is no strong link to a single environmental cause. A small number of cases are associated with inherited cancer predisposition syndromes, but the majority appear sporadically.
What Makes It Different From Alveolar Rhabdomyosarcoma
The two main types of rhabdomyosarcoma, embryonal and alveolar, look different under a microscope and behave differently in the body. ERMS cells appear as a mix of round and spindle-shaped cells at various stages of muscle development. Alveolar rhabdomyosarcoma (ARMS) cells are more uniform and arranged in a pattern that resembles tiny air sacs.
The most important distinction is genetic. About 85% of alveolar rhabdomyosarcomas carry a specific chromosomal rearrangement called a PAX-FOXO1 fusion, which drives the cancer’s aggressive behavior. ERMS lacks this fusion entirely. Instead, ERMS commonly involves changes on chromosome 11, specifically a region called 11p15.5, where the cell inherits two copies from the father and none from the mother. This difference matters because it affects how the cancer responds to treatment and what the long-term outlook looks like. Alveolar rhabdomyosarcoma with the fusion gene is generally considered more aggressive.
Histological Variants
Within ERMS, there are two notable subtypes. The botryoid variant grows as grape-like polyps that project into hollow organs, most often filling the lumen of the bladder or vagina. It accounts for roughly 5% of all rhabdomyosarcoma cases. The spindle cell variant, on the other hand, is more commonly found in paratesticular tumors. Both subtypes have historically been associated with a more favorable prognosis compared to classic embryonal rhabdomyosarcoma.
How It Is Diagnosed
Diagnosis requires a tissue biopsy. Pathologists examine the cells under a microscope looking for three key features: the characteristic mix of round and spindle-shaped cells, positive staining for a muscle protein called desmin, and a specific pattern of staining for markers called myogenin or MyoD1. In ERMS, these muscle markers show up in a scattered, patchy way across the tumor sample. This contrasts with alveolar rhabdomyosarcoma, where the same markers light up strongly and uniformly throughout the tissue.
Molecular testing plays a critical role in confirming the diagnosis. Pathologists specifically check for the absence of FOXO1 gene rearrangements. A tumor that looks like it could be either type under the microscope can be definitively classified as embryonal when this fusion gene is absent.
Staging and Grouping
Once ERMS is confirmed, doctors determine how far the disease has spread using a classification system developed by the Intergroup Rhabdomyosarcoma Study Group. This system assigns the tumor to one of four clinical groups based on how much disease remains after the initial surgery:
- Group I: The tumor was completely removed with clear margins and no lymph node involvement.
- Group II: The tumor was removed, but microscopic amounts of cancer remain at the edges, or nearby lymph nodes contain cancer cells.
- Group III: Only a biopsy was possible, or significant visible tumor remains after surgery.
- Group IV: The cancer has already spread to distant parts of the body at diagnosis.
This grouping, combined with the tumor’s location and the child’s age, determines the overall risk category and shapes the treatment plan.
Treatment Approach
ERMS is treated with a combination of chemotherapy, surgery, and often radiation. The standard chemotherapy regimen in North America uses three drugs: vincristine, actinomycin D, and cyclophosphamide, known together as the VAC protocol. In Europe, ifosfamide replaces cyclophosphamide in a regimen called IVA. Treatment cycles typically repeat every three weeks over many months.
Chemotherapy is often given before surgery (called neoadjuvant chemotherapy) to shrink the tumor and make complete surgical removal more feasible. This is especially important for tumors in locations where aggressive surgery would cause significant damage, like the head and face. After surgery, additional chemotherapy and sometimes radiation follow to eliminate any remaining cancer cells.
Radiation doses for ERMS tend to be somewhat lower than for alveolar rhabdomyosarcoma, reflecting the embryonal subtype’s relatively better response to treatment. The specific combination and intensity of therapy are tailored to the individual patient based on tumor location, group classification, and risk category.
Outlook and Survival
ERMS generally carries a better prognosis than alveolar rhabdomyosarcoma. Children with localized embryonal tumors in favorable sites, particularly the orbit and non-parameningeal head and neck locations, have the best outcomes, with long-term survival rates exceeding 90% in low-risk groups. Tumors in less favorable locations or those that have spread regionally still respond well to treatment, though survival rates are lower.
The biggest factor influencing outcomes is whether the disease has spread at the time of diagnosis. Children with metastatic ERMS (Group IV) face significantly tougher odds, with survival rates dropping substantially. Age also matters: children between 1 and 9 generally do better than infants under 1 or adolescents over 10. The absence of the PAX-FOXO1 fusion gene, which defines ERMS, is itself considered a favorable prognostic marker regardless of what the tumor looks like under the microscope.